Pfizer Inc. has announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI™ (marstacimab) for adults and adolescents with hemophilia A or B with inhibitors. The study demonstrated a statistically significant and clinically meaningful reduction in annualized bleeding rate compared to on-demand treatment in patients aged 12 and older. HYMPAVZI, administered as a once-weekly subcutaneous injection, showed a generally well-tolerated safety profile. Results from the full Phase 3 dataset are currently being analyzed, with additional data to be presented at upcoming medical meetings. Pfizer intends to discuss these findings with regulatory authorities to initiate filings for HYMPAVZI's approval for use in patients with hemophilia with inhibitors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。